A Multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in Red Blood Cell Transfusion-Dependent Subjects With Myelodysplastic Syndromes Associated With a Del (5q) Cytogenetic Abnormality
Latest Information Update: 12 Sep 2022
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 01 Sep 2022 Data from 3 studies (DS-003, MDS-004, and MDS-005) assessing impact of lenalidomide treatment on overall survival in patients with lower-risk myelodysplastic syndromes, published in the Clinical Lymphoma, Myeloma & Leukemia.
- 08 Dec 2015 Pooled analysis of 2 trials (n=286) including this study and another study [see CTP 700006777] were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 08 Dec 2015 Results of pooled analysis on conditional survival analysis (n=286), presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.